683 Capital Management LLC Has $3.88 Million Holdings in Leap Therapeutics, Inc. (NASDAQ:LPTX)

683 Capital Management LLC decreased its position in Leap Therapeutics, Inc. (NASDAQ:LPTX) by 2.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,350,000 shares of the company’s stock after selling 30,500 shares during the quarter. 683 Capital Management LLC owned approximately 3.52% of Leap Therapeutics worth $3,881,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of LPTX. Gilead Sciences Inc. acquired a new stake in shares of Leap Therapeutics during the 4th quarter valued at about $15,293,000. Monaco Asset Management SAM acquired a new position in Leap Therapeutics during the fourth quarter valued at approximately $592,000. BIT Capital GmbH grew its stake in Leap Therapeutics by 248.2% in the fourth quarter. BIT Capital GmbH now owns 282,008 shares of the company’s stock valued at $811,000 after acquiring an additional 201,008 shares during the period. Marshall Wace LLP raised its holdings in shares of Leap Therapeutics by 251.1% during the fourth quarter. Marshall Wace LLP now owns 185,690 shares of the company’s stock worth $535,000 after acquiring an additional 132,805 shares during the period. Finally, ADAR1 Capital Management LLC bought a new position in Leap Therapeutics in the fourth quarter valued at $305,000. Institutional investors and hedge funds own 30.46% of the company’s stock.

Analyst Upgrades and Downgrades

LPTX has been the topic of a number of research reports. Robert W. Baird lowered Leap Therapeutics from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $9.00 to $1.25 in a report on Wednesday, January 29th. HC Wainwright reissued a “neutral” rating on shares of Leap Therapeutics in a research note on Thursday, March 27th. Finally, Baird R W downgraded shares of Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 29th.

Leap Therapeutics Trading Down 0.7 %

Shares of NASDAQ LPTX opened at $0.42 on Friday. The business has a 50-day moving average of $0.38 and a 200-day moving average of $1.77. The firm has a market capitalization of $17.13 million, a price-to-earnings ratio of -0.22 and a beta of 0.22. Leap Therapeutics, Inc. has a 12 month low of $0.22 and a 12 month high of $4.79.

Leap Therapeutics (NASDAQ:LPTX) last issued its earnings results on Wednesday, March 26th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.02. On average, analysts predict that Leap Therapeutics, Inc. will post -1.84 earnings per share for the current year.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.